Stockscreener 앱 받기
60.27
1.43%
-0.875
시장 영업 전:
59.91
-0.36
-0.60%
Nektar Therapeutics 주식(NKTR)의 최신 뉴스
NKTR: 5,538 RSUs registered for resale via Morgan Stanley (NKTR) - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Shareholders to Reach Out - ACCESS Newswire
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Nektar Therapeutics: Shareholders Board Members Managers and Company Profile | US6402683063 - marketscreener.com
NKTR News | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill
Nektar Therapeutics (NKTR) Slips 1.5% Amid Consolidation Near Key Support LevelsFloat Adjusted Cap - newsline.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Is Nektar (NKTR) Betting Its Immunology Future on Rezpegaldesleukin’s Ambitious ZENITH-AD Phase 3 Program? - simplywall.st
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Gr - The National Law Review
A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Volatility - Yahoo Finance
Inventory turnover of Nektar Therapeutics – XETR:ITH0 - TradingView
Nektar Therapeutics 8-K SEC Filing: Company Details, Common Stock, and NASDAQ Listing (June 2026) - Minichart
Diluted net income available to common stockholders of Nektar Therapeutics – XETR:ITH0 - TradingView
A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Pullback - simplywall.st
What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock - Insider Monkey
Nektar Therapeutics (NKTR) holders back plan share boost and auditor at 2026 meeting - Stock Titan
NKTR Stock Skyrockets: Wall Street Sees Up To 200% Upside As Skin Trial Crushes Even Bull-Case Forecasts - Stocktwits
NKTR: All proposals passed; immunology pipeline advances with REZPEG entering phase III trials - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Investors to Connect - The National Law Review
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Investors to Inquire about Securities Investigation - ACCESS Newswire
Drug developers outpace Nasdaq Bio, rezpeg data sends up Nektar - BioWorld News
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York - The AI Journal
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch - AOL.com
Nektar Therapeutics to webcast at 2026 Jefferies Global Healthcare Conference on June 3 - Pluang
How to watch Nektar’s Jefferies healthcare fireside chat on June 3 - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Stockholders to Reach Out - ACCESS Newswire
Interim CFO at Nektar Therapeutics (NKTR) files initial Form 3 ownership report - Stock Titan
Why I'm Still Neutral On Nektar Therapeutics After Alopecia Areata Extension Data (NKTR) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire
A Look At Nektar Therapeutics (NKTR) Valuation After Prosight’s US$10 Million Purchase Ahead Of Phase 3 Trial - simplywall.st
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch - The Motley Fool
Prosight Management Increases Stake in Nektar Therapeutics - Intellectia AI
Nektar TherapeuticsCommon Stock (NQ: NKTR - The Chronicle-Journal
NKTR Stock Price, Quote & Chart | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill
Nektar Therapeutics R&D chief sells $13,036 in shares - Investing.com UK
Nektar Therapeutics CEO Robin Howard W sells $29,086 in shares By Investing.com - Investing.com South Africa
Nektar Therapeutics R&D chief sells $13,036 in shares By Investing.com - Investing.com South Africa
Nektar Therapeutics CEO Robin Howard W sells $29,086 in shares - Investing.com
1.27%
1.43%
자본화:
|
볼륨(24시간):